A citation-based method for searching scientific literature

D L Hertz, H L McLeod. Clin Pharmacol Ther 2016
Times Cited: 12







List of co-cited articles
38 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
William J Irvin, Christine M Walko, Karen E Weck, Joseph G Ibrahim, Wing K Chiu, E Claire Dees, Susan G Moore, Oludamilola A Olajide, Mark L Graham, Sean T Canale,[...]. J Clin Oncol 2011
131
25

Pharmacogenetics: from bench to byte--an update of guidelines.
J J Swen, M Nijenhuis, A de Boer, L Grandia, A H Maitland-van der Zee, H Mulder, G A P J M Rongen, R H N van Schaik, T Schalekamp, D J Touw,[...]. Clin Pharmacol Ther 2011
612
25

Pharmacogenomics in the clinic.
Mary V Relling, William E Evans. Nature 2015
401
25



Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.
L V Kalman, Jag Agúndez, M Lindqvist Appell, J L Black, G C Bell, S Boukouvala, C Bruckner, E Bruford, K Caudle, S A Coulthard,[...]. Clin Pharmacol Ther 2016
94
16

Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients.
Kazuma Kiyotani, Taisei Mushiroda, Chiyo K Imamura, Yusuke Tanigawara, Naoya Hosono, Michiaki Kubo, Mitsunori Sasa, Yusuke Nakamura, Hitoshi Zembutsu. Breast Cancer Res Treat 2012
65
16

Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.
P Saladores, T Mürdter, D Eccles, B Chowbay, N K Zgheib, S Winter, B Ganchev, B Eccles, S Gerty, A Tfayli,[...]. Pharmacogenomics J 2015
100
16

CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.
Wendy A Teft, Inna Y Gong, Brian Dingle, Kylea Potvin, Jawaid Younus, Theodore A Vandenberg, Muriel Brackstone, Francisco E Perera, Yun-Hee Choi, Guangyong Zou,[...]. Breast Cancer Res Treat 2013
51
16

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
V O Dezentjé, F L Opdam, H Gelderblom, J Hartigh den, T Van der Straaten, R Vree, E Maartense, C H Smorenburg, H Putter, A S Dieudonné,[...]. Breast Cancer Res Treat 2015
40
16

CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer.
Richard R Love, Zuerenesay Desta, David Flockhart, Todd Skaar, Evan T Ogburn, Anuradha Ramamoorthy, Gemma B Uy, Adriano V Laudico, Nguyen Van Dinh, Le Hong Quang,[...]. Springerplus 2013
27
16

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
C Davies, J Godwin, R Gray, M Clarke, D Cutter, S Darby, P McGale, H C Pan, C Taylor, Y C Wang,[...]. Lancet 2011
16

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.
L Madlensky, L Natarajan, S Tchu, M Pu, J Mortimer, S W Flatt, D M Nikoloff, G Hillman, M R Fontecha, H J Lawrence,[...]. Clin Pharmacol Ther 2011
222
16

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.
A Gaedigk, S D Simon, R E Pearce, L D Bradford, M J Kennedy, J S Leeder. Clin Pharmacol Ther 2008
510
16

Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications.
Stephen Bernard, Kathleen A Neville, Anne T Nguyen, David A Flockhart. Oncologist 2006
186
16

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
M A Province, M P Goetz, H Brauch, D A Flockhart, J M Hebert, R Whaley, V J Suman, W Schroth, S Winter, H Zembutsu,[...]. Clin Pharmacol Ther 2014
118
16

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Meredith M Regan, Brian Leyland-Jones, Mark Bouzyk, Olivia Pagani, Weining Tang, Roswitha Kammler, Patrizia Dell'orto, Maria Olivia Biasi, Beat Thürlimann, Maria B Lyng,[...]. J Natl Cancer Inst 2012
237
16

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
James M Rae, Suzy Drury, Daniel F Hayes, Vered Stearns, Jacklyn N Thibert, Ben P Haynes, Janine Salter, Ivana Sestak, Jack Cuzick, Mitch Dowsett. J Natl Cancer Inst 2012
184
16

Personalized Critical Care Medicine: How Far Away Are We?
Amy M Ahasic, David C Christiani. Semin Respir Crit Care Med 2015
8
25

HLA-B*5701 screening for hypersensitivity to abacavir.
Simon Mallal, Elizabeth Phillips, Giampiero Carosi, Jean-Michel Molina, Cassy Workman, Janez Tomazic, Eva Jägel-Guedes, Sorin Rugina, Oleg Kozyrev, Juan Flores Cid,[...]. N Engl J Med 2008
16

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
Magnus Ingelman-Sundberg, Sarah C Sim, Alvin Gomez, Cristina Rodriguez-Antona. Pharmacol Ther 2007
768
16

Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.
S G Leckband, J R Kelsoe, H M Dunnenberger, A L George, E Tran, R Berger, D J Müller, M Whirl-Carrillo, K E Caudle, M Pirmohamed. Clin Pharmacol Ther 2013
147
16

Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey.
E J Stanek, C L Sanders, K A Johansen Taber, M Khalid, A Patel, R R Verbrugge, B C Agatep, R E Aubert, R S Epstein, F W Frueh. Clin Pharmacol Ther 2012
283
16

Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth.
Rajen J Mody, Yi-Mi Wu, Robert J Lonigro, Xuhong Cao, Sameek Roychowdhury, Pankaj Vats, Kevin M Frank, John R Prensner, Irfan Asangani, Nallasivam Palanisamy,[...]. JAMA 2015
239
16

Pharmacogenomics in the curricula of colleges and schools of pharmacy in the United States.
John E Murphy, James S Green, Laura A Adams, Robert B Squire, Grace M Kuo, Alan McKay. Am J Pharm Educ 2010
91
16


Personalized oncology through integrative high-throughput sequencing: a pilot study.
Sameek Roychowdhury, Matthew K Iyer, Dan R Robinson, Robert J Lonigro, Yi-Mi Wu, Xuhong Cao, Shanker Kalyana-Sundaram, Lee Sam, O Alejandro Balbin, Michael J Quist,[...]. Sci Transl Med 2011
430
16

Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Daniel L Hertz, Allison Deal, Joseph G Ibrahim, Christine M Walko, Karen E Weck, Steven Anderson, Gustav Magrinat, Oludamilola Olajide, Susan Moore, Rachel Raab,[...]. Oncologist 2016
28
16

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
Ursula Amstutz, Linda M Henricks, Steven M Offer, Julia Barbarino, Jan H M Schellens, Jesse J Swen, Teri E Klein, Howard L McLeod, Kelly E Caudle, Robert B Diasio,[...]. Clin Pharmacol Ther 2018
213
16

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.
J A Luzum, R E Pakyz, A R Elsey, C E Haidar, J F Peterson, M Whirl-Carrillo, S K Handelman, K Palmer, J M Pulley, M Beller,[...]. Clin Pharmacol Ther 2017
84
16

A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia.
Jennifer R Donnan, Wendy J Ungar, Maria Mathews, Rebecca L Hancock-Howard, Proton Rahman. Pediatr Blood Cancer 2011
30
16

Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update.
M V Relling, E E Gardner, W J Sandborn, K Schmiegelow, C-H Pui, S W Yee, C M Stein, M Carrillo, W E Evans, J K Hicks,[...]. Clin Pharmacol Ther 2013
232
16

Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry.
Takaya Moriyama, Yung-Li Yang, Rina Nishii, Hany Ariffin, Chengcheng Liu, Ting-Nien Lin, Wenjian Yang, Dong-Tsamn Lin, Chih-Hsiang Yu, Shirley Kham,[...]. Blood 2017
61
16

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
K R Crews, A Gaedigk, H M Dunnenberger, T E Klein, D D Shen, J T Callaghan, E D Kharasch, T C Skaar. Clin Pharmacol Ther 2012
258
16

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.
R S Gammal, M H Court, C E Haidar, O F Iwuchukwu, A H Gaur, M Alvarellos, C Guillemette, J L Lennox, M Whirl-Carrillo, S S Brummel,[...]. Clin Pharmacol Ther 2016
94
16

Personalized genomic analyses for cancer mutation discovery and interpretation.
Siân Jones, Valsamo Anagnostou, Karli Lytle, Sonya Parpart-Li, Monica Nesselbush, David R Riley, Manish Shukla, Bryan Chesnick, Maura Kadan, Eniko Papp,[...]. Sci Transl Med 2015
252
16

Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
Kasmintan A Schrader, Donavan T Cheng, Vijai Joseph, Meera Prasad, Michael Walsh, Ahmet Zehir, Ai Ni, Tinu Thomas, Ryma Benayed, Asad Ashraf,[...]. JAMA Oncol 2016
184
16

Medical decision support systems and therapeutics: The role of autopilots.
R L Woosley, J Whyte, A Mohamadi, K Romero. Clin Pharmacol Ther 2016
11
9




Direct-to-consumer genetic testing: Perspectives on its value in healthcare.
S K Delaney, M F Christman. Clin Pharmacol Ther 2016
7
14

Industry perspectives on biomarker qualification.
G Lavezzari, A W Womack. Clin Pharmacol Ther 2016
15
8

The Legal Environment for Precision Medicine.
B Thompson, J Boiani. Clin Pharmacol Ther 2016
4
25

Real-world data in the molecular era-finding the reality in the real world.
D J Dickson, J D Pfeifer. Clin Pharmacol Ther 2016
8
12

Precision medicine in the age of big data: The present and future role of large-scale unbiased sequencing in drug discovery and development.
P Vicini, O Fields, E Lai, E D Litwack, A-M Martin, T M Morgan, M A Pacanowski, M Papaluca, O D Perez, M S Ringel,[...]. Clin Pharmacol Ther 2016
23
8

Providing Access to Genomic Variant Knowledge in a Healthcare Setting: A Vision for the ClinGen Electronic Health Records Workgroup.
C L Overby, B Heale, S Aronson, J M Cherry, S Dwight, A Milosavljevic, T Nelson, A Niehaus, M A Weaver, E M Ramos,[...]. Clin Pharmacol Ther 2016
10
10

"Precision" drug development?
J Woodcock. Clin Pharmacol Ther 2016
8
12

Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.
Eduardo Martinez de Dueñas, Enrique Ochoa Aranda, Isabel Blancas Lopez-Barajas, Teresa Ferrer Magdalena, Fernando Bandrés Moya, Luis Miguel Chicharro García, José A Gómez Capilla, Mercedes Zafra Ceres, Tomás de Haro, Regina Romero Llorens,[...]. Breast 2014
29
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.